ABSTRACT
Neurodegenerative disorders are becoming prevalent with the increasing age of the general population. A number of difficulties have emerged for the potential treatment of neurodegenerative diseases, as these disorders may be multi systemic in nature. Due to limitations regarding the blood brain barrier (BBB) structure, efflux pumps and metabolic enzyme expression, conventional drug delivery systems do not provide efficient therapy for neurodegenerative disorders. Nanotechnology can offer impressive improvement of the neurodegenerative disease treatment by using bio-engineered systems interacting with biological systems at a molecular level. This review focuses on the nano-enabled system applications for the treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer’s, Parkinson’s and Prion diseases.
Similar content being viewed by others
REFERENCES
Ellison D, Love S, Chimelli L, Harding BN, Lowe J, Vinters HV. Neuropathology: A reference text of CNS pathology. London: Mosby; 2004.
Beal MF, Lang AE, Ludolph AC. Neudegenerative diseases: neurobiology, pathogenesis and therapeutics. Cambridge: Cambridge University Press; 2005.
Cacciatore I, Baldassarre L, Fornasari E, Mollica A, Pinnen F. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxide Med Cell Longev. 2012. doi:10.1155/2012/240146.
Whalley K. Neurodegenerative disease: undoing aggregation. Nat Rev Neurosci. 2008;9:83.
Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163(2):495–529.
Burridge S. Neurodegenerative diseases: novel route to neuroprotection. Nat Rev Drug Discov. 2012;11:906–7.
Waldmeier PC, Tatton WG. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discov Today. 2004;9(5):210–8.
Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res. 2010;62:166–78.
Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Nanomed Nanotech Biol Med. 2012; (Suppl 1):S51-S58.
Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154–72.
Nowacek A, Gendelman E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4(5):557–74.
Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol. 2009;88(4):272–85.
Barchet T, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv. 2009;6(3):211–25.
Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s Disease and Parkinson’s Disease). J Drug Deliv. 2011;2011:1–12.
Awad RA. Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson’s disease. World J Gastroenterol. 2011;17(46):5035–48.
Poole CP, Owens FJ. Introduction to nanotechnology. New Jersey: Wiley; 2003.
Vo-Dinh T. Nanotechnology in biology and medicine: methods, devices, and applications. Boca Raton: CRC Press Taylor & Francis Group; 2007.
Cho Y, Borgens RB. Polymer and nano-technology applications for repair and reconstruction of the central nervous system. Exp Neurol. 2012;233(1):126–44.
Mahmood M, Casciano D, Xu Y, Biris AS. Engineered nanostructural materials for application in cancer biology and medicine. J Appl Toxicol. 2012;32(1):10–9.
Leucuta SE. Nanotechnology for delivery of drugs and biomedical applications. Curr Clin Pharmacol. 2010;5(4):257–80.
Silva GA. Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS. BMC Neurosci. 2008;9 Suppl 3:S1–4.
Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract. 2008;17(2):89–101.
Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv. 2012;3(2):181–94.
Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol. 2010;10(12):7906–18.
Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging:a concise review. Nanomed Nanotech Biol Med. 2005;1:193–212.
Manish G, Sharma V. Targeted drug delivery system: a review. Res J Chem Sci. 2011;1(2):135–8.
Petrak K. Nanotechnology and site-targeted drug delivery. J Biomater Sci Polym Ed. 2006;17(11):1209–19.
Paulo CS, Pires das Neves R, Ferreira LS. Nanoparticles for intracellular-targeted drug delivery. Nanotechnology. 2011;22(49):1–11.
Gagliardi M, Bardi G, Bifone A. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the CNS. Ther Deliv. 2012;3(7):875–87.
Srikanth M, Kessler JA. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol. 2012;8(6):307–18.
De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome blood–brain barrier. Curr Drug Metab. 2012;13(1):61–9.
Mangas-Sanjuan V, González-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Drug penetration across the blood–brain barrier: an overview. Ther Deliv. 2010;1(4):535–62.
Tucker IG, Yang L, Mujoo H. Delivery of drugs to the brain via the blood brain barrier using colloidal carriers. J Microencapsul. 2012;29(5):475–86.
Urquhart BL, Kim RB. Blood–brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol. 2009;65(11):1063–70.
Geldenhuys WJ, Allen DD, Bloomquist JR. Novel models for assessing blood–brain barrier drug permeation. Expert Opin Drug Metab Toxicol. 2012;8(6):647–53.
Orthmann A, Fichtner I, Zeisig R. Improving the transport of chemotherapeutic drugs across the blood–brain barrier. Expert Rev Clin Pharmacol. 2011;4(4):477–90.
Potschka H. Targeting the brain–surmounting or bypassing the blood–brain barrier. Handb Exp Pharmacol. 2010;197:411–31.
Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target. 2010;18(3):157–67.
Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010;40(5):385–403.
Burov S, Leko M, Dorosh M, Dobrodumov A, Veselkina O. Creatinyl amino acids: new hybrid compounds with neuroprotective activity. J Pept Sci. 2011;17(9):620–6.
Liu Y, Hu Y, Guo Y, Ma H, Li J, Jiang C. Targeted imaging of activated caspase-3 in the central nervous system by a dual functional nano-device. J Control Release. 2012;163(2):203–10.
Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials. 2012;33(29):7194–205.
Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251–6.
Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release. 2012;159(3):429–34.
Chang J, Paillard A, Passirani C, Morille M, Benoit JP, Betbeder D, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res. 2012;29(6):1495–505.
Kuo YC, Lin PI, Wang CC. Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles. Nanomedicine (Lond). 2011;6(6):1011–26.
Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V. Brain delivery of transferrin coupled indinavir submicron lipid emulsions–pharmacokinetics and tissue distribution. Colloids Surf B Biointerfaces. 2011;86(2):305–13.
Jain A, Chasoo G, Singh SK, Saxena AK, Jain SK. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J Microencapsul. 2011;28(1):21–8.
Yemişci M, Gürsoy-Özdemir Y, Caban S, Bodur E, Capan Y, Dalkara T. Transport of a caspase inhibitor across the blood–brain barrier by chitosan nanoparticles. Methods Enzymol. 2012;508:253–69.
Shao K, Huang R, Li J, Han L, Ye L, Lou J, et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release. 2010;147(1):118–26.
Zhao M, Chang J, Fu X, Liang C, Liang S, Yan R, et al. Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats. J Drug Target. 2012;20(5):416–21.
Dakwar GR, Abu Hammad I, Popov M, Linder C, Grinberg S, Heldman E, et al. Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles. J Control Release. 2012;160(2):315–21.
Agarwal A, Agrawal H, Tiwari S, Jain S, Agrawal GP. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting. Int J Pharm. 2011;421(1):189–201.
Di Carlo M, Giacomazza D, San Biagio PL. Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools. J Phys Condens Matter. 2012;24(24):1–17.
Eskici G, Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer’s disease. Biochemistry. 2012;51(32):6289–311.
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–22.
Mohamed T, Rao PP. Alzheimer’s disease: emerging trends in small molecule therapies. Curr Med Chem. 2011;18(28):4299–320.
Loef M, Walach H. Copper and iron in Alzheimer’s disease: a systematic review and its dietary implications. Br J Nutr. 2012;107(1):7–19.
Galimberti D, Scarpini E. Progress in Alzheimer’s disease. J Neurol. 2012;259(2):201–11.
Di Stefano A, Lannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin Drug Deliv. 2011;8(5):581–603.
Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One. 2012;7(3):1–10.
Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545–61.
Mozafari MR. Nanoliposomes: preparation and analysis. Methods Mol Biol. 2010;605:29–50.
Hardy J. Alzheimer’s disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis. 2006;9:151–3.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.
Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98.
Crouch PJ, Barnham KJ, Bush AI, White AR. Therapeutic treatments for Alzheimer’s disease based on metal bioavailability. Drug News Perspect. 2006;19:469–74.
Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta. 2005;1741:246–52.
Smith MA. Oxidative stress and iron imbalance in Alzheimer disease: howrust became the fuss! J Alzheimers Dis. 2006;9:305–8.
Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, Ndesendo VM, et al. Surface-engineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with β-Amyloid aggregates of Alzheimer’s disease. Pharm Res. 2012;29(11):3075–89.
Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett. 2009;455(3):187–90.
Lopez OL, Rabin BS, Huff FJ, Rezek D, Reinmuth OM. Serum autoantibodies in patients with Alzheimer’s disease and vascular dementia and in nondemented control subjects. Stroke. 1992;23:1078–83.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–5.
Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer’s disease. Mol Med Today. 1999;5:343–50.
Fradinger EA, Monien BH, Urbanc B, Lomakin A, Tan M, Li H, et al. C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity. Proc Natl Acad Sci U S A. 2008;105:14175–80.
Songjiang Z, Lixiang W. Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech. 2009;10(3):900–5.
Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathy. Pharm Res. 2008;25(11):2674–84.
Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007;102:420–33.
Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials. 2011;32(6):1635–45.
Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, Salmona M, et al. Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol. 2010;156(4):341–6.
Fang YP, Tsai YH, Wu PC, Huang YB. Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm. 2008;356:144–52.
Mishra D, Mishra PK, Dabadghao S, Dubey V, Nahar M, Jain NK. Comparative evaluation of hepatitis B surface antigen-loaded elastic liposomes and ethosomes for human dendritic cell uptake and immune response. Nanomedicine. 2010;6:110–8.
Zhao L, Wei MJ, He M, Jin WB, Zhao HS, Yao WF. The effects of tetramethylpyrazine on learning and memory abilities of mice with Alzheimer disease and its possible mechanism. Chin Pharmacol Bull. 2008;24:1088–92.
Shi J, Wang Y, Luo G. Ligustrazine phosphate ethosomes for treatment of Alzheimer’s disease, in vitro and in animal model studies. AAPS PharmSciTech. 2012;13(2):485–92.
Beg S, Samad A, Alam MI, Nazish I. Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. CNS Neurol Disord Drug Targets. 2011;10(5):576–88.
Sharma A, Gautam SP, Gupta AK. Surface modified dendrimers: synthesis and characterization for cancer targeted drug delivery. Bioorg Med Chem. 2011;19(11):3341–6.
Wasiak T, Ionov M, Nieznanski K, Nieznanska H, Klementieva O, Granell M, et al. Phosphorus dendrimers affect Alzheimer’s (Aβ1-28) peptide and MAP-Tau protein aggregation. Mol Pharm. 2012;9(3):458–69.
Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine. 2012;7:2077–86.
Xiang Y, Wu Q, Liang L, Wang X, Wang J, Zhang X, et al. Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson’s disease in the MPTP-induced mice model. J Drug Target. 2012;20(1):67–75.
Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm. 2011;419(1–2):296–307.
Fahn S. Levodopa in the treatment of Parkinson’s disease. J Neural Transm Suppl. 2006;71:1–15.
Black KJ, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS. Rapid intravenous loading of levodopa for human research: clinical results. J Neurosci Methods. 2003;127(1):19–29.
During MJ, Freese A, Deutch AY, Kibat PG, Sabel BA, Langer R, et al. Biochemical and behavioral recovery in a rodent model of Parkinson’s disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol. 1992;115(2):193–9.
Muthuprasanna P, Manisha M, Suriaprabha K, Srinivasa Rao T, Anbu J. Formulation and psychopharmacological evaluation of surfactant modified liposome for parkinsonism disease. Asian J Pharm Clin Res. 2010;3(1):46–54.
Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 2008;25(7):1521–30.
Zhao Y, Haney MJ, Klyachko NL, Li S, Booth SL, Higginbotham SM, et al. Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles. Nanomedicine (Lond). 2011;6(1):25–42.
Azeem A, Talegaonkar S, Negi LM, Ahmad FJ, Khar RK, Iqbal Z. Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm. 2012;422(1–2):436–44.
Pillay S, Pillay V, Choonara YE, Naidoo D, Khan RA, du Toit LC, et al. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm. 2009;382(1–2):277–90.
Rekas A, Lo V, Gadd GE, Cappai R, Yun SI. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson’s disease-related protein. Macromol Biosci. 2009;9(3):230–8.
Malvindi MA, Di Corato R, Curcio A, Melisi D, Rimoli MG, Tortiglione C, et al. Multiple functionalization of fluorescent nanoparticles for specific biolabeling and drug delivery of dopamine. Nanoscale. 2011;3(12):5110–9.
Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm. 2011;415(1–2):273–83.
Marandi Y, Farahi N, Sadeghi A, Sadeghi-Hashjin G. Prion diseases - current theories and potential therapies: a brief review. Folia Neuropathol. 2012;50(1):46–9.
Imran M, Mahmood S. An overview of human prion diseases. Virol J. 2011;8:1–9.
Lloyd S, Mead S, Collinge J. Genetics of prion disease. Top Curr Chem. 2011;305:1–22.
Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J. Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer’s and prion diseases. Biochem Biophys Res Commun. 2006;339(2):577–82.
Skaat H, Belfort G, Margel S. Synthesis and characterization of fluorinated magnetic core-shell nanoparticles for inhibition of insulin amyloid fibril formation. Nanotechnology. 2009;20(22):1–9.
Sousa F, Mandal S, Garrovo C, Astolfo A, Bonifacio A, Latawiec D, et al. Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale. 2010;2(12):2826–34.
Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A, et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J Neurosci Methods. 2001;111(2):151–5.
Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D, et al. Translocation of poly(ethylene glycolco- hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells:role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules. 2007;8:793–9.
Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrinreceptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71:251–6.
Monteiro-Riviere NA, Lang TC. Nanotoxicology: characterization, dosing and health effects. New York: Informa Health Care USA, Inc; 2007.
Jia G, Wang H, Yan L, Wang X, Pei R, Yan T, et al. Cytotoxicity of carbon nanomaterials: single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol. 2005;39(5):1378–83.
Wang J, Sun P, Bao Y, Liu J, An L. Cytotoxicity of single-walled carbon nanotubes on PC12 cells. Toxicol In Vitro. 2011;25(1):242–50.
Deng X, Luan Q, Chen W, Wang Y, Wu M, Zhang H, et al. Nanosized zinc oxide particles induce neural stem cell apoptosis. Nanotechnology. 2009;20(11):1–7.
Hussain SM, Javorina AK, Schrand AM, Duhart HM, Ali SF, Schlager JJ. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci. 2006;92(2):456–63.
Long TC, Saleh N, Tilton RD, Lowry GV, Veronesi B. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ Sci Technol. 2006;40(14):4346–52.
Pisanic 2nd TR, Blackwell JD, Shubayev VI, Fiñones RR, Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials. 2007;28(16):2572–81.
Zhang QL, Li MQ, Ji JW, Gao FP, Bai R, Chen CY, et al. In vivo toxicity of nano-alumina on mice neurobehavioral profiles and the potential mechanisms. Int J Immunopathol Pharmacol. 2011;24(1 Suppl):23S–9S.
Wu J, Wang C, Sun J, Xue Y. Neurotoxicity of silica nanoparticles: brain localization and dopaminergic neurons damage pathways. ACS Nano. 2011;5(6):4476–89.
Win-Shwe TT, Fujimaki H. Nanoparticles and neurotoxicity. Int J Mol Sci. 2011;12:6267–80.
Thassu D, Deleers M, Pathak Y. Nanoparticulate Drug Delivery Systems. New York: Informa Healthcare USA, Inc.; 2007.
Sharma HS, Sharma A. Recent Perspectives on Nanoneuroprotection & Nanoneurotoxicity. CNS Neurol Disord Drug Target. 2012;11(1):1–2.
Hu YL, Gao JQ. Potential neurotoxicity of nanoparticles. Int J Pharm. 2010;94(1–2):115–21.
ACKNOWLEDGMENTS AND DISCLOSURES
This paper does not reflect any financial, commercial, or other relationship between the author and any other party.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bozdağ Pehlivan, S. Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases. Pharm Res 30, 2499–2511 (2013). https://doi.org/10.1007/s11095-013-1156-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-013-1156-7